Healthcare

• Chimeric Therapeutics is rethinking its cancer cell therapy strategy because safety limits in its CDH17 CAR-T trial stopped.

CERE-CALM is a randomised, double-blind, sham-controlled study registered as ACTRN12626000738325. It is designed to recruit 66 participants, with a minimum of 60, who must be aged 50 or over. Participants will be randomised two to one between active treatment and sham treatment. Each will …

The company's lead asset is CYV-101, which it describes as a first-in-class fusion protein that binds and neutralises the growth factors VEGF-C and VEGF-D. The LAM program is currently in Stage 1, which covers preclinical biology and inhalation studies. Work in the quarter included …

DMX-200 is being developed for focal segmental glomerulosclerosis (FSGS), a kidney disease. Dimerix said aggregate upfront licensing receipts across its five regional deals now exceed A$80 million, with potential milestone payments totalling about A$1.9 billion plus royalties on net sales. Milestones are contingent on …

Cash receipts for the quarter were about A$1.6m, and the company said roughly A$725,000 of earned revenue remained to be collected. Cash at quarter end was A$4.745m, down from A$7.290m at the end of the previous quarter.

Revenue was about US$0.9m in the quarter, flat on the second quarter. Annual recurring revenue for the Ensight product was about US$760,000 at quarter end, with a further US$360,000 contracted but waiting to go live. Operating cash outflow was US$2.45m, which the company attributed …

An independent review by Dr Mathew Moore of ResearchDx attributed the variability mainly to differences in how samples were collected and handled before analysis. It recommended optimising extracellular vesicle capture, biomarker selection and sample collection.